Evidence map›Paper›PMID 37631370›Full record

ReviewPharmaceutics2023

Harnessing the Potential of Biosurfactants for Biomedical and Pharmaceutical Applications.

Chiara Ceresa, Letizia Fracchia, Andrea Chiara Sansotera, Mayri Alejandra Díaz De Rienzo, Ibrahim M Banat

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Microorganisms · 2026
    Article
  6. Review
  7. Review
  8. HalotolerantRSC advances · 2026
    Article
  9. Review
  10. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Review
  11. Marine-DerivedMicroorganisms · 2026
    Article
  12. Article
  13. Molecules (Basel, Switzerland) · 2025
    Review
  14. VaginalBiofilm · 2025
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chiara CeresaDepartment of Pharmaceutical Sciences, Università del Piemonte Orientale "A. Avogadro", 28100 Novara, Italy.
Letizia FracchiaDepartment of Pharmaceutical Sciences, Università del Piemonte Orientale "A. Avogadro", 28100 Novara, Italy.ORCID 0000-0003-3505-1919
Andrea Chiara SansoteraDepartment of Pharmaceutical Sciences, Università del Piemonte Orientale "A. Avogadro", 28100 Novara, Italy.ORCID 0009-0000-3681-3220
Mayri Alejandra Díaz De RienzoSchool of Science, Engineering and Environment, University of Salford, Manchester M5 4WT, UK.
Ibrahim M BanatPharmaceutical Science Research Group, Biomedical Science Research Institute, Ulster University, Coleraine BT52 1SA, UK.ORCID 0000-0001-8964-2840

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biosurfactants (BSs) are microbial compounds that have emerged as potential alternatives to chemical surfactants due to their multifunctional properties, sustainability and biodegradability. Owing to their amphipathic nature and distinctive structural arrangement, biosurfactants exhibit a range of physicochemical properties, including excellent surface activity, efficient critical micelle concentration, humectant properties, foaming and cleaning abilities and the capacity to form microemulsions. Furthermore, numerous biosurfactants display additional biological characteristics, such as antibacterial, antifungal and antiviral effects, and antioxidant, anticancer and immunomodulatory activities. Over the past two decades, numerous studies have explored their potential applications, including pharmaceuticals, cosmetics, antimicrobial and antibiofilm agents, wound healing, anticancer treatments, immune system modulators and drug/gene carriers. These applications are particularly important in addressing challenges such as antimicrobial resistance and biofilm formations in clinical, hygiene and therapeutic settings. They can also serve as coating agents for surfaces, enabling antiadhesive, suppression, or eradication strategies. Not least importantly, biosurfactants have shown compatibility with various drug formulations, including nanoparticles, liposomes, micro- and nanoemulsions and hydrogels, improving drug solubility, stability and bioavailability, and enabling a targeted and controlled drug release. These qualities make biosurfactants promising candidates for the development of next-generation antimicrobial, antibiofilm, anticancer, wound-healing, immunomodulating, drug or gene delivery agents, as well as adjuvants to other antibiotics. Analysing the most recent literature, this review aims to update the present understanding, highlight emerging trends, and identify promising directions and advancements in the utilization of biosurfactants within the pharmaceutical and biomedical fields.

Indexed as

antiadhesive-coatingsantibacterial/antifungal/antiviral activityantibiofilm agentsanticancer agentsbiosurfactantsdrug delivery systemsimmunomodulatory activityLABmarine producerswound-healing promoters

Identifiers

PMID37631370
PMCPMC10457971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.